The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

Cell Cycle

Volumn 8, Issue 1, 2009, Pages 88-96

  Vazquez Martin, Alejandro ^a   Oliveras Ferraros, Cristina ^a   Menendez, Javier A ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

AMPK; Breast cancer; HER2; Metformin; mTOR; Reactive oxygen species; S6K1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; AMP ACTIVATED PROTEIN KINASE KINASE; AMP-ACTIVATED PROTEIN KINASE KINASE; ANTIDIABETIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; S6 KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; ONCOGENE NEU; PROTEIN EXPRESSION; PROTEIN TARGETING; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE;

ANIMALIA; MUS;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PROTEIN KINASES; RECEPTOR, ERBB-2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TIME FACTORS;

EID: 60749108023     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.1.7499     Document Type: Article

References (57)

1. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-5.
2. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29:254-8.
3. Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacological interventions? J Clin Oncol 2008; 26:833-4.
4. Hede K. Doctors seek to prevent breast cancer recurrence by lowering insulin levels. J Natl Cancer Inst 2008; 100:530-2.
5. Strack T. Metformin: a review. Drugs Today (Barc) 2008; 44:303-14.
6. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003; 63:1879-94.
7. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008; 358:47-54.
8. Rotella CM, Monami M, Mannucci E. Metformin beyond diabetes: new life for an old drug. Curr Diabetes Rev 2006; 2:307-15.
9. Golay A. Metformin and body weight. Int J Obes (Lond) 2008; 32:61-72.
10. Carling D. AMP-activated protein kinase: balancing the scales. Biochimie 2005; 87:87-91.
11. Schimmack G, Defronzo RA, Musi N. AMP-activated protein kinase: Role in metabolism and therapeutic implications. Diabetes Obes Metab 2006; 8:591-602.
12. Lee JH, Koh H, Kim M, Kim Y, Lee SY, Karess RE, et al. Energy-dependent regulation of cell structure by AMP-activated protein kinase. Nature 2007; 447:1017-20.
13. Kuhajda FP. AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int J Obes (Lond) 2008; 32:36-41.
14. Brenman JE. AMPK/LKB1 signaling in epithelial cell polarity and cell division. Cell Cycle 2007; 6:2755-9.
15. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66:10269-73.
16. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804-12.
17. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007; 64:1232-90.
18. Jiang W, Zhu Z, Thompson HJ. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by lmiting energy availability with 2-deoxyglucose. Mol Carcinog 2008; 47:616-28.
19. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412:211-21.
20. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 2008; 67:1-7.
21. Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL, Bacus SS. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 2008; 1769-75.
22. Zakikhani M, Dowling R, Sonenberg N, Pollak M. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 2008; 1:369-75.
23. Brunet J, Vazquez-Martin A, Colomer R, Graña-Suarez B, Martin-Castillo B, Menendez JA. BRCA1 and acetyl-CoA Carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog 2008; 47:157-63.
24. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, et al. Metformin suppresses intestinal polyp growth in Apc(Min/+) mice. Cancer Sci 2008; 99:2136-41.
25. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 110:246-50.
26. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67:6745-52.
27. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008; 15:833-9.
28. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 2008; in press.
29. Hadad SM, Appleyard V, Thompson AM. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 2008; in press.
30. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40:685-93.
31. Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, et al. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 2005; 139:721-3.
32. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovicj IG, Zabezhinski MA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008; 7:2769-73.
33. Vazquez-Martin A, Oliveras-Ferraros C, Colomer R, Brunet J, Menendez JA. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann Oncol 2008; 19:1097-109.
34. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62:4132-41.
35. Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005; 304:604-19.
36. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167-74.
37. Swinnen JV, Beckers A, Brusselmans K, Organe S, Segers J, Timmermans L, et al. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 2005; 65:2441-8.
38. Blagosklonny MV, Campisi J. Cancer and aging: more puzzles, more promises? Cell Cycle 2008; 7:2615-8.
39. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27:3576-86.
40. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004; 101:10715-20.
41. Menendez JA, Lupu R, Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 2005; 18:375-85.
42. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7:763-77.
43. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 2008; 41:59-85.
44. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Común 2004; 321:161-7.
45. Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, et al. Upregulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 2007; 282:26122-31.
46. Chiang CT, Way TD, Tsai SJ, Lin JK. Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett 2007; 581:5735-42.
47. Chajès V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 2006; 66:5287-94.
48. Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X, et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and p70S6K1 in human ovarian cancer cells. Free Radic Biol Med 2006; 41:1521-33.
49. Zhou Q, Liu LZ, Fu B, Hu X, Shi X, Fang J, et al. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 2007; 28:28-37.
50. Bonnefont-Rousselot D, Raji B, Walrand S, Gardès-Albert M, Jore D, Legrand A, et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 2003; 52:586-9.
51. Ouslimani N, Peynet J, Bonnefont-Rousselot D, Thérond P, Legrand A, Beaudeux JL. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 2005; 54:829-34.
52. Kanigür-Sultuybek G, Ozdas SB, Curgunlu A, Tezcan V, Onaran I. Does metformin prevent short-term oxidant-induced dna damage? In vitro study on lymphocytes from aged subjects. J Basic Clin Physiol Pharmacol 2007; 18:129-40.
53. Ota K, Nakamura J, Li W, Kozakae M, Watarai A, Nakamura N, et al. Metformin prevents methylglyoxal-induced apoptosis of mouse Schwann cells. Biochem Biophys Res Commun 2007; 357:270-5.
54. Sum CF, Webster JM, Johnson AB, Catalano C, Cooper BG, Taylor R. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med 9:61-5.
55. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24:49-57.
56. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther 2008; 7:1520-4.
57. Blagosklonny MV. Aging: ROS or TOR. Cell Cycle 2008; 7:in press.